{"ID": "DDI-DrugBank.d765.s0.p0", "TEXT1": "CYP3A4 Inhibitors: The drug metabolizing enzyme CYP3A4 inhibitor ketoconazole, when coadministered to subjects who were poor metabolizers, significantly increased plasma concentrations of tolterodine (see CLINICAL PHARMACOLOGY, Variability in Metabolism and Drug-Drug Interactions).", "LBL": "DDI-mechanism", "DRUGA": ["Ketoconazole", "drug", "19-30"], "DRUGB": ["tolterodine", "drug", "135-145"]}
{"ID": "DDI-DrugBank.d765.s1.p0", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. This is to help avoid any potential drug interactions.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "23-34"], "DRUGB": ["azole antifungals", "group", "84-100"]}
{"ID": "DDI-DrugBank.d765.s1.p1", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "23-34"], "DRUGB": ["itraconazole", "drug", "107-118"]}
{"ID": "DDI-DrugBank.d765.s1.p2", "TEXT1": "If you are taking ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "23-34"], "DRUGB": ["miconazole", "drug", "121-130"]}
{"ID": "DDI-DrugBank.d765.s1.p3", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors, such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the maximum recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "23-34"], "DRUGB": ["macrolide antibiotics", "group", "136-156"]}
{"ID": "DDI-DrugBank.d765.s1.p4", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "23-34"], "DRUGB": ["erythromycin", "drug", "163-174"]}
{"ID": "DDI-DrugBank.d765.s1.p5", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "23-34"], "DRUGB": ["clarithromycin", "drug", "177-190"]}
{"ID": "DDI-DrugBank.d765.s1.p6", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole), macrolide antibiotics (eg, erythromycin, clarithromycin), cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "23-34"], "DRUGB": ["cyclosporine", "drug", "196-207"]}
{"ID": "DDI-DrugBank.d765.s1.p7", "TEXT1": "The recommended dose of DETROL LA for patients receiving ketoconazole or other potent CYP3A4 inhibitors is 2 mg daily.", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "23-34"], "DRUGB": ["vinblastine", "drug", "212-222"]}
{"ID": "DDI-DrugBank.d765.s1.p8", "TEXT1": "Ketoconazole and other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine can increase the level of DETROL LA in the body. As a result, the recommended dose of DETROL LA for patients receiving these medications is 2 mg daily.", "LBL": "DDI-advise", "DRUGA": ["ketoconazole", "drug", "23-34"], "DRUGB": ["DETROL LA", "brand", "249-257"]}
{"ID": "DDI-DrugBank.d765.s1.p9", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, a lower dose of DETROL LA (2 mg daily) is recommended.", "LBL": "0", "DRUGA": ["azole antifungals", "group", "84-100"], "DRUGB": ["itraconazole", "drug", "107-118"]}
{"ID": "DDI-DrugBank.d765.s1.p10", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["azole antifungals", "group", "84-100"], "DRUGB": ["miconazole", "drug", "121-130"]}
{"ID": "DDI-DrugBank.d765.s1.p11", "TEXT1": "If you are taking ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["azole antifungals", "group", "84-100"], "DRUGB": ["macrolide antibiotics", "group", "136-156"]}
{"ID": "DDI-DrugBank.d765.s1.p12", "TEXT1": "For patients taking ketoconazole or other potent CYP3A4 inhibitors (such as other azole antifungals, like itraconazole or miconazole, or macrolide antibiotics, like erythromycin or clarithromycin), the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["azole antifungals", "group", "84-100"], "DRUGB": ["erythromycin", "drug", "163-174"]}
{"ID": "DDI-DrugBank.d765.s1.p13", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, a reduced dose of DETROL LA is recommended at 2 mg daily.", "LBL": "0", "DRUGA": ["azole antifungals", "group", "84-100"], "DRUGB": ["clarithromycin", "drug", "177-190"]}
{"ID": "DDI-DrugBank.d765.s1.p14", "TEXT1": "For patients receiving ketoconazole or other CYP3A4 inhibitors such as azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["azole antifungals", "group", "84-100"], "DRUGB": ["cyclosporine", "drug", "196-207"]}
{"ID": "DDI-DrugBank.d765.s1.p15", "TEXT1": "If you are taking ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole), macrolide antibiotics (eg, erythromycin, clarithromycin), cyclosporine, or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["azole antifungals", "group", "84-100"], "DRUGB": ["vinblastine", "drug", "212-222"]}
{"ID": "DDI-DrugBank.d765.s1.p16", "TEXT1": "For patients receiving potent CYP3A4 inhibitors such as ketoconazole, itraconazole, miconazole, erythromycin, clarithromycin, cyclosporine, or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "DDI-advise", "DRUGA": ["azole antifungals", "group", "84-100"], "DRUGB": ["DETROL LA", "brand", "249-257"]}
{"ID": "DDI-DrugBank.d765.s1.p17", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["itraconazole", "drug", "107-118"], "DRUGB": ["miconazole", "drug", "121-130"]}
{"ID": "DDI-DrugBank.d765.s1.p18", "TEXT1": "If you are taking ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["itraconazole", "drug", "107-118"], "DRUGB": ["macrolide antibiotics", "group", "136-156"]}
{"ID": "DDI-DrugBank.d765.s1.p19", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily. This is to help avoid any potentialconvulsions that could occur.", "LBL": "0", "DRUGA": ["itraconazole", "drug", "107-118"], "DRUGB": ["erythromycin", "drug", "163-174"]}
{"ID": "DDI-DrugBank.d775.s10.p1", "TEXT1": "Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as MIVACRON include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.", "LBL": "DDI-int", "DRUGA": ["nondepolarizing agents", "drug", "67-88"], "DRUGB": ["antibiotics", "group", "123-133"]}
{"ID": "DDI-DrugBank.d765.s1.p21", "TEXT1": "When taking ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["itraconazole", "drug", "107-118"], "DRUGB": ["cyclosporine", "drug", "196-207"]}
{"ID": "DDI-DrugBank.d765.s1.p22", "TEXT1": "The recommended dose of DETROL LA for patients receiving ketoconazole or other potent CYP3A4 inhibitors is 2 mg daily.", "LBL": "0", "DRUGA": ["itraconazole", "drug", "107-118"], "DRUGB": ["vinblastine", "drug", "212-222"]}
{"ID": "DDI-DrugBank.d765.s1.p23", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, it is recommended that they take a 2 mg dose of DETROL LA daily.", "LBL": "DDI-advise", "DRUGA": ["itraconazole", "drug", "107-118"], "DRUGB": ["DETROL LA", "brand", "249-257"]}
{"ID": "DDI-DrugBank.d765.s1.p24", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA should not exceed 2 mg daily.", "LBL": "0", "DRUGA": ["miconazole", "drug", "121-130"], "DRUGB": ["macrolide antibiotics", "group", "136-156"]}
{"ID": "DDI-DrugBank.d591.s3.p0", "TEXT1": "The use of Ropivacaine in patients who are also taking strong inhibitors of cytochrome P4501A2, such as fluvoxamine, may result in increased plasma levels of Ropivacaine.", "LBL": "DDI-int", "DRUGA": ["fluvoxamine", "drug", "54-64"], "DRUGB": ["Ropivacaine", "drug", "112-122"]}
{"ID": "DDI-DrugBank.d765.s1.p26", "TEXT1": "If you are receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["miconazole", "drug", "121-130"], "DRUGB": ["clarithromycin", "drug", "177-190"]}
{"ID": "DDI-DrugBank.d765.s1.p27", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["miconazole", "drug", "121-130"], "DRUGB": ["cyclosporine", "drug", "196-207"]}
{"ID": "DDI-DrugBank.d765.s1.p28", "TEXT1": "Patients who are receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine should be prescribed a dose of DETROL LA that is 2 mg daily.", "LBL": "0", "DRUGA": ["miconazole", "drug", "121-130"], "DRUGB": ["vinblastine", "drug", "212-222"]}
{"ID": "DDI-DrugBank.d765.s1.p29", "TEXT1": "For patients receiving other medications that can inhibit CYP3A4 (such as ketoconazole, itraconazole, miconazole, erythromycin, clarithromycin, cyclosporine, or vinblastine), the recommended dose of DETROL LA is 2 mg daily.", "LBL": "DDI-advise", "DRUGA": ["miconazole", "drug", "121-130"], "DRUGB": ["DETROL LA", "brand", "249-257"]}
{"ID": "DDI-DrugBank.d765.s1.p30", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors, the recommended dose of DETROL LA is 2 mg daily. This is to help avoid any potential interactions that may occur.", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "136-156"], "DRUGB": ["erythromycin", "drug", "163-174"]}
{"ID": "DDI-DrugBank.d765.s1.p31", "TEXT1": "If you are being treated with ketoconazole or another potent CYP3A4 inhibitor, such as another azole antifungal (eg, itraconazole, miconazole), a macrolide antibiotic (eg, erythromycin, clarithromycin), or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "136-156"], "DRUGB": ["clarithromycin", "drug", "177-190"]}
{"ID": "DDI-DrugBank.d765.s1.p32", "TEXT1": "If a patient is receiving ketoconazole or other potent CYP3A4 inhibitors, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "136-156"], "DRUGB": ["cyclosporine", "drug", "196-207"]}
{"ID": "DDI-DrugBank.d765.s1.p33", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (e.g., itraconazole, miconazole) or macrolide antibiotics (e.g., erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg per day.", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "136-156"], "DRUGB": ["vinblastine", "drug", "212-222"]}
{"ID": "DDI-DrugBank.d765.s1.p34", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "DDI-advise", "DRUGA": ["macrolide antibiotics", "group", "136-156"], "DRUGB": ["DETROL LA", "brand", "249-257"]}
{"ID": "DDI-DrugBank.d765.s1.p35", "TEXT1": "When taking DETROL LA along with other medications that may increase its potency, the recommended dose is 2 mg daily. These include ketoconazole, other azole antifungals, macrolide antibiotics, cyclosporine, and vinblastine.", "LBL": "0", "DRUGA": ["erythromycin", "drug", "163-174"], "DRUGB": ["clarithromycin", "drug", "177-190"]}
{"ID": "DDI-DrugBank.d765.s1.p36", "TEXT1": "If you are taking ketoconazole or other strong CYP3A4 inhibitors such as other azole antifungals (e.g., itraconazole, miconazole), macrolide antibiotics (e.g., erythromycin, clarithromycin), cyclosporine, or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["erythromycin", "drug", "163-174"], "DRUGB": ["cyclosporine", "drug", "196-207"]}
{"ID": "DDI-DrugBank.d765.s1.p37", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["erythromycin", "drug", "163-174"], "DRUGB": ["vinblastine", "drug", "212-222"]}
{"ID": "DDI-DrugBank.d765.s1.p38", "TEXT1": "When ketoconazole or other potent CYP3A4 inhibitors are being taken, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "DDI-advise", "DRUGA": ["erythromycin", "drug", "163-174"], "DRUGB": ["DETROL LA", "brand", "249-257"]}
{"ID": "DDI-DrugBank.d765.s1.p39", "TEXT1": "If you are taking ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "177-190"], "DRUGB": ["cyclosporine", "drug", "196-207"]}
{"ID": "DDI-DrugBank.d765.s1.p40", "TEXT1": "If you are taking ketoconazole or other potent CYP3A4 inhibitors, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "177-190"], "DRUGB": ["vinblastine", "drug", "212-222"]}
{"ID": "DDI-DrugBank.d765.s1.p41", "TEXT1": "Patients receiving ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine should use a lower dose of DETROL LA, such as 2 mg daily.", "LBL": "DDI-advise", "DRUGA": ["clarithromycin", "drug", "177-190"], "DRUGB": ["DETROL LA", "brand", "249-257"]}
{"ID": "DDI-DrugBank.d765.s1.p42", "TEXT1": "If you are taking ketoconazole or other potent CYP3A4 inhibitors such as other azole antifungals (eg, itraconazole, miconazole) or macrolide antibiotics (eg, erythromycin, clarithromycin) or cyclosporine or vinblastine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "0", "DRUGA": ["cyclosporine", "drug", "196-207"], "DRUGB": ["vinblastine", "drug", "212-222"]}
{"ID": "DDI-DrugBank.d765.s1.p43", "TEXT1": "For patients receiving ketoconazole or other potent CYP3A4 inhibitors, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "DDI-advise", "DRUGA": ["cyclosporine", "drug", "196-207"], "DRUGB": ["DETROL LA", "brand", "249-257"]}
{"ID": "DDI-DrugBank.d765.s1.p44", "TEXT1": "If you are taking ketoconazole, itraconazole, miconazole, erythromycin, clarithromycin, or cyclosporine, the recommended dose of DETROL LA is 2 mg daily.", "LBL": "DDI-advise", "DRUGA": ["vinblastine", "drug", "212-222"], "DRUGB": ["DETROL LA", "brand", "249-257"]}
{"ID": "DDI-DrugBank.d670.s0.p0", "TEXT1": "Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. However, as with any drug, it is always advisable to check with your healthcare provider before taking any new medications.", "LBL": "0", "DRUGA": ["INVEGA", "brand", "14-19"], "DRUGB": ["Paliperidone", "drug", "46-57"]}
{"ID": "DDI-DrugBank.d670.s6.p0", "TEXT1": "Paliperidone has primary CNS effects, so INVEGA should be used with caution in combination with other central nervous system drugs and alcohol.", "LBL": "0", "DRUGA": ["paliperidone", "drug", "33-44"], "DRUGB": ["INVEGA", "brand", "47-52"]}
{"ID": "DDI-DrugBank.d670.s6.p1", "TEXT1": "Given the primary CNS effects of paliperidone, INVEGA should be used with caution in combination with other drugs that have central nervous system effects, and alcohol.", "LBL": "DDI-advise", "DRUGA": ["paliperidone", "drug", "33-44"], "DRUGB": ["centrally acting drugs", "group", "111-132"]}
{"ID": "DDI-DrugBank.d670.s6.p2", "TEXT1": "Given the primary CNS effects of paliperidone, INVEGA should be used with caution in combination with other drugs that affect the central nervous system.", "LBL": "DDI-advise", "DRUGA": ["paliperidone", "drug", "33-44"], "DRUGB": ["alcohol", "drug", "138-144"]}
{"ID": "DDI-DrugBank.d670.s6.p3", "TEXT1": "Given the potential for central nervous system effects with paliperidone, it is recommended that it be used with caution in combination with other centrally acting drugs or alcohol.", "LBL": "DDI-advise", "DRUGA": ["INVEGA", "brand", "47-52"], "DRUGB": ["centrally acting drugs", "group", "111-132"]}
{"ID": "DDI-DrugBank.d670.s6.p4", "TEXT1": "Given the primary CNS effects of paliperidone, INVEGA should be used with caution in combination with other drugs that act on the central nervous system, and alcohol.", "LBL": "DDI-advise", "DRUGA": ["INVEGA", "brand", "47-52"], "DRUGB": ["alcohol", "drug", "138-144"]}
{"ID": "DDI-DrugBank.d670.s6.p5", "TEXT1": "Given the primary CNS effects of paliperidone, INVEGA should be used with caution in combination with other centrally acting drugs and alcohol.", "LBL": "0", "DRUGA": ["centrally acting drugs", "group", "111-132"], "DRUGB": ["alcohol", "drug", "138-144"]}
{"ID": "DDI-DrugBank.d670.s7.p0", "TEXT1": "Paliperidone may lessen the effect of levodopa and other dopamine agonists.", "LBL": "DDI-effect", "DRUGA": ["Paliperidone", "drug", "0-11"], "DRUGB": ["levodopa", "drug", "42-49"]}
{"ID": "DDI-DrugBank.d670.s7.p1", "TEXT1": "Paliperidone may reduce the effectiveness of levodopa and other dopamine agonists.", "LBL": "DDI-effect", "DRUGA": ["Paliperidone", "drug", "0-11"], "DRUGB": ["dopamine agonists", "group", "61-77"]}
{"ID": "DDI-DrugBank.d670.s7.p2", "TEXT1": "Paliperidone may reduce the effectiveness of levodopa and other dopamine agonists.", "LBL": "0", "DRUGA": ["levodopa", "drug", "42-49"], "DRUGB": ["dopamine agonists", "group", "61-77"]}
{"ID": "DDI-DrugBank.d670.s9.p0", "TEXT1": "The potential for other drugs to affect INVEGA is low since paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19. Therefore, an interaction with inhibitors or inducers of these isozymes is unlikely.", "LBL": "0", "DRUGA": ["INVEGA", "brand", "36-41"], "DRUGB": ["Paliperidone", "drug", "46-57"]}
{"ID": "DDI-DrugBank.d784.s0.p0", "TEXT1": "The concurrent use of oxybutynin with other drugs that cause dry mouth, constipation, drowsiness, or other anticholinergic effects may increase the frequency and/or severity of those effects.", "LBL": "DDI-effect", "DRUGA": ["oxybutynin", "drug", "23-32"], "DRUGB": ["anticholinergic drugs", "group", "45-65"]}
{"ID": "DDI-DrugBank.d784.s3.p0", "TEXT1": "Mean oxybutynin chloride plasma concentrations were approximately 2 fold higher when DITROPAN XL was administered with ketoconazole, a potentially potent CYP3A4 inhibitor.", "LBL": "0", "DRUGA": ["oxybutynin chloride", "drug", "5-23"], "DRUGB": ["DITROPAN XL", "brand", "85-95"]}
{"ID": "DDI-DrugBank.d784.s3.p1", "TEXT1": "When DITROPAN XL is used with ketoconazole, a potent CYP3A4 inhibitor, mean oxybutynin chloride plasma concentrations may be approximately 2 times higher.", "LBL": "0", "DRUGA": ["oxybutynin chloride", "drug", "5-23"], "DRUGB": ["ketoconazole", "drug", "119-130"]}
{"ID": "DDI-DrugBank.d784.s3.p2", "TEXT1": "When DITROPAN XL was administered with ketoconazole, a potent CYP3A4 inhibitor, mean oxybutynin chloride plasma concentrations were approximately 2 fold higher.", "LBL": "DDI-mechanism", "DRUGA": ["DITROPAN XL", "brand", "85-95"], "DRUGB": ["ketoconazole", "drug", "119-130"]}
{"ID": "DDI-DrugBank.d784.s4.p0", "TEXT1": "Other substances that inhibit the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter the mean pharmacokinetic parameters of oxybutynin (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["antimycotic agents", "group", "67-84"], "DRUGB": ["itraconazole", "drug", "93-104"]}
{"ID": "DDI-DrugBank.d784.s4.p1", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may change oxybutynin's mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["antimycotic agents", "group", "67-84"], "DRUGB": ["miconazole", "drug", "110-119"]}
{"ID": "DDI-DrugBank.d784.s4.p2", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may change oxybutynin's mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["antimycotic agents", "group", "67-84"], "DRUGB": ["macrolide antibiotics", "group", "125-145"]}
{"ID": "DDI-DrugBank.d784.s4.p3", "TEXT1": "Other drugs that inhibit the cytochrome P450 3A4 enzyme system, such as antifungal agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter the mean pharmacokinetic parameters of oxybutynin (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["antimycotic agents", "group", "67-84"], "DRUGB": ["erythromycin", "drug", "154-165"]}
{"ID": "DDI-DrugBank.d784.s4.p4", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may impact oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["antimycotic agents", "group", "67-84"], "DRUGB": ["clarithromycin", "drug", "171-184"]}
{"ID": "DDI-DrugBank.d784.s4.p5", "TEXT1": "Other agents that inhibit the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter the mean pharmacokinetic parameters of oxybutynin (i.e., Cmax and AUC).", "LBL": "DDI-mechanism", "DRUGA": ["antimycotic agents", "group", "67-84"], "DRUGB": ["oxybutynin", "drug", "198-207"]}
{"ID": "DDI-DrugBank.d784.s4.p6", "TEXT1": "Other drugs that inhibit the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter the mean pharmacokinetic parameters of oxybutynin (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["itraconazole", "drug", "93-104"], "DRUGB": ["miconazole", "drug", "110-119"]}
{"ID": "DDI-DrugBank.d784.s4.p7", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin's mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["itraconazole", "drug", "93-104"], "DRUGB": ["macrolide antibiotics", "group", "125-145"]}
{"ID": "DDI-DrugBank.d784.s4.p8", "TEXT1": "If other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), are used together with oxybutynin, it may alter the oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["itraconazole", "drug", "93-104"], "DRUGB": ["erythromycin", "drug", "154-165"]}
{"ID": "DDI-DrugBank.d784.s4.p9", "TEXT1": "Other drugs that inhibit the cytochrome P450 3A4 enzyme system may alter the mean pharmacokinetic parameters of oxybutynin (i.e., maximum concentration [Cmax] and area under the curve [AUC]). These other drugs include antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin).", "LBL": "0", "DRUGA": ["itraconazole", "drug", "93-104"], "DRUGB": ["clarithromycin", "drug", "171-184"]}
{"ID": "DDI-DrugBank.d784.s4.p10", "TEXT1": "Other drugs which inhibit the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter the mean pharmacokinetic parameters of oxybutynin (i.e., Cmax and AUC).", "LBL": "DDI-mechanism", "DRUGA": ["itraconazole", "drug", "93-104"], "DRUGB": ["oxybutynin", "drug", "198-207"]}
{"ID": "DDI-DrugBank.d784.s4.p11", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), can affect oxybutynin's mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["miconazole", "drug", "110-119"], "DRUGB": ["macrolide antibiotics", "group", "125-145"]}
{"ID": "DDI-DrugBank.d784.s4.p12", "TEXT1": "Other drugs that inhibit the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter the mean pharmacokinetic parameters of oxybutynin (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["miconazole", "drug", "110-119"], "DRUGB": ["erythromycin", "drug", "154-165"]}
{"ID": "DDI-DrugBank.d784.s4.p13", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may have an impact on oxybutynin's mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["miconazole", "drug", "110-119"], "DRUGB": ["clarithromycin", "drug", "171-184"]}
{"ID": "DDI-DrugBank.d784.s4.p14", "TEXT1": "Other drugs which inhibit the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter the mean pharmacokinetic parameters of oxybutynin (i.e., Cmax and AUC).", "LBL": "DDI-mechanism", "DRUGA": ["miconazole", "drug", "110-119"], "DRUGB": ["oxybutynin", "drug", "198-207"]}
{"ID": "DDI-DrugBank.d784.s4.p15", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), could potentially alter oxybutynin mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "125-145"], "DRUGB": ["erythromycin", "drug", "154-165"]}
{"ID": "DDI-DrugBank.d784.s4.p16", "TEXT1": "Other substances that inhibit the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin's mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "125-145"], "DRUGB": ["clarithromycin", "drug", "171-184"]}
{"ID": "DDI-DrugBank.d784.s4.p17", "TEXT1": "Other medications that inhibit the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may change the way oxybutynin works in the body (i.e., Cmax and AUC).", "LBL": "DDI-mechanism", "DRUGA": ["macrolide antibiotics", "group", "125-145"], "DRUGB": ["oxybutynin", "drug", "198-207"]}
{"ID": "DDI-DrugBank.d784.s4.p18", "TEXT1": "Other medications that inhibit the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may change oxybutynin's mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "154-165"], "DRUGB": ["clarithromycin", "drug", "171-184"]}
{"ID": "DDI-DrugBank.d784.s4.p19", "TEXT1": "Other inhibitors of the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may alter oxybutynin's mean pharmacokinetic parameters (i.e., Cmax and AUC).", "LBL": "DDI-mechanism", "DRUGA": ["erythromycin", "drug", "154-165"], "DRUGB": ["oxybutynin", "drug", "198-207"]}
{"ID": "DDI-DrugBank.d784.s4.p20", "TEXT1": "The concomitant administration of other medications that inhibit the cytochrome P450 3A4 enzyme system, such as antimycotic agents (e.g., itraconazole and miconazole) or macrolide antibiotics (e.g., erythromycin and clarithromycin), may affect the mean pharmacokinetic parameters (i.e., Cmax and AUC) of oxybutynin.", "LBL": "DDI-mechanism", "DRUGA": ["clarithromycin", "drug", "171-184"], "DRUGB": ["oxybutynin", "drug", "198-207"]}
{"ID": "DDI-DrugBank.d784.s7.p0", "TEXT1": "Description: Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["antacid", "group", "24-30"], "DRUGB": ["antacid", "group", "42-48"]}
{"ID": "DDI-DrugBank.d784.s7.p1", "TEXT1": "Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["antacid", "group", "24-30"], "DRUGB": ["aluminum hydroxide", "drug", "61-78"]}
{"ID": "DDI-DrugBank.d784.s7.p2", "TEXT1": "Taking antacid concurrently did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["antacid", "group", "24-30"], "DRUGB": ["magnesium hydroxide", "drug", "81-99"]}
{"ID": "DDI-DrugBank.d784.s7.p3", "TEXT1": "There is no significant effect on the exposure of oxybutynin or desethyloxybutynin when antacid is taken concurrently.", "LBL": "0", "DRUGA": ["antacid", "group", "24-30"], "DRUGB": ["simethicone", "drug", "106-116"]}
{"ID": "DDI-DrugBank.d784.s7.p4", "TEXT1": "There was no significant difference in the exposure to oxybutynin or desethyloxybutynin when taking antacid concurrently.", "LBL": "0", "DRUGA": ["antacid", "group", "24-30"], "DRUGB": ["oxybutynin", "drug", "164-173"]}
{"ID": "DDI-DrugBank.d784.s7.p5", "TEXT1": "It is not known whether concurrent ingestion of antacid will significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["antacid", "group", "24-30"], "DRUGB": ["desethyloxybutynin", "drug_n", "178-195"]}
{"ID": "DDI-DrugBank.d784.s7.p6", "TEXT1": "Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly lower the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["antacid", "group", "42-48"], "DRUGB": ["aluminum hydroxide", "drug", "61-78"]}
{"ID": "DDI-DrugBank.d784.s7.p7", "TEXT1": "Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["antacid", "group", "42-48"], "DRUGB": ["magnesium hydroxide", "drug", "81-99"]}
{"ID": "DDI-DrugBank.d784.s7.p8", "TEXT1": "Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["antacid", "group", "42-48"], "DRUGB": ["simethicone", "drug", "106-116"]}
{"ID": "DDI-DrugBank.d784.s7.p9", "TEXT1": "The concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not have a significant impact on the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["antacid", "group", "42-48"], "DRUGB": ["oxybutynin", "drug", "164-173"]}
{"ID": "DDI-DrugBank.d784.s7.p10", "TEXT1": "Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) had no significant effect on the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["antacid", "group", "42-48"], "DRUGB": ["desethyloxybutynin", "drug_n", "178-195"]}
{"ID": "DDI-DrugBank.d784.s7.p11", "TEXT1": "Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["aluminum hydroxide", "drug", "61-78"], "DRUGB": ["magnesium hydroxide", "drug", "81-99"]}
{"ID": "DDI-DrugBank.d784.s7.p12", "TEXT1": "Concurrent use of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) does not appear to significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["aluminum hydroxide", "drug", "61-78"], "DRUGB": ["simethicone", "drug", "106-116"]}
{"ID": "DDI-DrugBank.d784.s7.p13", "TEXT1": "It does not appear that concurrent ingestion of antacid significantly affects the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["aluminum hydroxide", "drug", "61-78"], "DRUGB": ["oxybutynin", "drug", "164-173"]}
{"ID": "DDI-DrugBank.d784.s7.p14", "TEXT1": "The concurrent administration of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["aluminum hydroxide", "drug", "61-78"], "DRUGB": ["desethyloxybutynin", "drug_n", "178-195"]}
{"ID": "DDI-DrugBank.d784.s7.p15", "TEXT1": "Concurrent ingestion of antacid did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["magnesium hydroxide", "drug", "81-99"], "DRUGB": ["simethicone", "drug", "106-116"]}
{"ID": "DDI-DrugBank.d784.s7.p16", "TEXT1": "Concurrent ingestion of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["magnesium hydroxide", "drug", "81-99"], "DRUGB": ["oxybutynin", "drug", "164-173"]}
{"ID": "DDI-DrugBank.d784.s7.p17", "TEXT1": "Concurrent ingestion of antacid did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["magnesium hydroxide", "drug", "81-99"], "DRUGB": ["desethyloxybutynin", "drug_n", "178-195"]}
{"ID": "DDI-DrugBank.d784.s7.p18", "TEXT1": "Concurrent ingestion of antacid did not significantly affect the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["simethicone", "drug", "106-116"], "DRUGB": ["oxybutynin", "drug", "164-173"]}
{"ID": "DDI-DrugBank.d784.s7.p19", "TEXT1": "Simultaneous consumption of antacid (20 mL of antacid containing aluminum hydroxide, magnesium hydroxide, and simethicone) did not have a significant impact on the exposure of oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["simethicone", "drug", "106-116"], "DRUGB": ["desethyloxybutynin", "drug_n", "178-195"]}
{"ID": "DDI-DrugBank.d784.s7.p20", "TEXT1": "Concurrent intake of antacid did not have a significant effect on exposure to oxybutynin or desethyloxybutynin.", "LBL": "0", "DRUGA": ["oxybutynin", "drug", "164-173"], "DRUGB": ["desethyloxybutynin", "drug_n", "178-195"]}
{"ID": "DDI-DrugBank.d717.s0.p0", "TEXT1": "Mitotane has been reported to speed up the metabolism of warfarin by the mechanism of hepatic microsomal enzyme induction, which could lead to an increase in the dosage requirements for warfarin.", "LBL": "DDI-mechanism", "DRUGA": ["Mitotane", "drug", "0-7"], "DRUGB": ["warfarin", "drug", "59-66"]}
{"ID": "DDI-DrugBank.d717.s0.p1", "TEXT1": "Mitotane has been reported to affect the metabolism of warfarin, potentially resulting in the need for a higher dosage of warfarin.", "LBL": "0", "DRUGA": ["Mitotane", "drug", "0-7"], "DRUGB": ["warfarin", "drug", "175-182"]}
{"ID": "DDI-DrugBank.d717.s0.p2", "TEXT1": "It is recommended that patients on warfarin treatment should be monitored closely when starting treatment with mitotane, as the latter may lead to an increase in dosage requirements for warfarin.", "LBL": "0", "DRUGA": ["warfarin", "drug", "59-66"], "DRUGB": ["warfarin", "drug", "175-182"]}
{"ID": "DDI-DrugBank.d717.s1.p0", "TEXT1": "When administering @DRUG$ to patients who are also taking coumarin-type anticoagulants, physicians should closely monitor patients for a change in their dosage requirements.", "LBL": "0", "DRUGA": ["anticoagulant", "group", "70-82"], "DRUGB": ["Mitotane", "drug", "123-130"]}
{"ID": "DDI-DrugBank.d717.s1.p1", "TEXT1": "Because of this potential interaction, patients taking coumarin-type anticoagulants should be closely monitored when starting treatment with Mitotane.", "LBL": "0", "DRUGA": ["anticoagulant", "group", "70-82"], "DRUGB": ["coumarin-type anticoagulants", "group", "147-174"]}
{"ID": "DDI-DrugBank.d717.s1.p2", "TEXT1": "Physicians should closely monitor patients for a change in anticoagulant dosage requirements when administering Mitotane to patients on coumarin-type anticoagulants.", "LBL": "DDI-advise", "DRUGA": ["Mitotane", "drug", "123-130"], "DRUGB": ["coumarin-type anticoagulants", "group", "147-174"]}
{"ID": "DDI-DrugBank.d669.s0.p0", "TEXT1": "There have been reports of erythema and histamine-like flushing and anaphylactoid reactions when vancomycin is administered alongside anesthetic agents.", "LBL": "DDI-effect", "DRUGA": ["vancomycin", "drug", "30-39"], "DRUGB": ["anesthetic agents", "group", "45-61"]}
{"ID": "DDI-DrugBank.d669.s1.p0", "TEXT1": "Some other drugs can have negative effects when taken with AUGMENTIN XR, so it's important to be monitored carefully when taking this drug.", "LBL": "0", "DRUGA": ["amphotericin B", "drug", "119-132"], "DRUGB": ["aminoglycosides", "group", "135-149"]}
{"ID": "DDI-DrugBank.d669.s1.p1", "TEXT1": "Other potentially neurotoxic or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, should be used with caution when concurrent or sequential use is indicated. Close monitoring is recommended.", "LBL": "0", "DRUGA": ["amphotericin B", "drug", "119-132"], "DRUGB": ["bacitracin", "drug", "152-161"]}
{"ID": "DDI-DrugBank.d669.s1.p2", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires close monitoring.", "LBL": "0", "DRUGA": ["amphotericin B", "drug", "119-132"], "DRUGB": ["polymyxin B", "drug", "164-174"]}
{"ID": "DDI-DrugBank.d669.s1.p3", "TEXT1": "Other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, should be used concurrently and/or sequentially with caution and under careful monitoring.", "LBL": "0", "DRUGA": ["amphotericin B", "drug", "119-132"], "DRUGB": ["colistin", "drug", "177-184"]}
{"ID": "DDI-DrugBank.d669.s1.p4", "TEXT1": "Other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, should be used concurrently and/or sequentially with @DRUG$ with careful monitoring.", "LBL": "0", "DRUGA": ["amphotericin B", "drug", "119-132"], "DRUGB": ["viomycin", "drug", "187-194"]}
{"ID": "DDI-DrugBank.d669.s1.p5", "TEXT1": "The use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, concurrently or sequentially, requires careful monitoring.", "LBL": "0", "DRUGA": ["amphotericin B", "drug", "119-132"], "DRUGB": ["cisplatin", "drug", "200-208"]}
{"ID": "DDI-DrugBank.d669.s1.p6", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring and close supervision.", "LBL": "0", "DRUGA": ["aminoglycosides", "group", "135-149"], "DRUGB": ["bacitracin", "drug", "152-161"]}
{"ID": "DDI-DrugBank.d669.s1.p7", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires monitoring.", "LBL": "0", "DRUGA": ["aminoglycosides", "group", "135-149"], "DRUGB": ["polymyxin B", "drug", "164-174"]}
{"ID": "DDI-DrugBank.d669.s1.p8", "TEXT1": "Other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, should be used with caution and monitored closely when indicated.", "LBL": "0", "DRUGA": ["aminoglycosides", "group", "135-149"], "DRUGB": ["colistin", "drug", "177-184"]}
{"ID": "DDI-DrugBank.d669.s1.p9", "TEXT1": "Other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, require careful monitoring when used concurrently and/or sequentially with @DRUG$.", "LBL": "0", "DRUGA": ["aminoglycosides", "group", "135-149"], "DRUGB": ["viomycin", "drug", "187-194"]}
{"ID": "DDI-DrugBank.d669.s1.p10", "TEXT1": "The concomitant administration of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring.", "LBL": "0", "DRUGA": ["aminoglycosides", "group", "135-149"], "DRUGB": ["cisplatin", "drug", "200-208"]}
{"ID": "DDI-DrugBank.d669.s1.p11", "TEXT1": "caution should be used when prescribing @DRUG$ concurrently or sequentially with other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin.", "LBL": "0", "DRUGA": ["bacitracin", "drug", "152-161"], "DRUGB": ["polymyxin B", "drug", "164-174"]}
{"ID": "DDI-DrugBank.d669.s1.p12", "TEXT1": "If you are using other potentially neurotoxic or nephrotoxic drugs such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, you will need to be carefully monitored.", "LBL": "0", "DRUGA": ["bacitracin", "drug", "152-161"], "DRUGB": ["colistin", "drug", "177-184"]}
{"ID": "DDI-DrugBank.d669.s1.p13", "TEXT1": "When indicated, the concurrent or sequential use of other potentially neurotoxic or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, requires careful monitoring.", "LBL": "0", "DRUGA": ["bacitracin", "drug", "152-161"], "DRUGB": ["viomycin", "drug", "187-194"]}
{"ID": "DDI-DrugBank.d669.s1.p14", "TEXT1": "Concurrent or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, requires careful monitoring.", "LBL": "0", "DRUGA": ["bacitracin", "drug", "152-161"], "DRUGB": ["cisplatin", "drug", "200-208"]}
{"ID": "DDI-DrugBank.d669.s1.p15", "TEXT1": "Other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, need to be monitored carefully when used concurrently and/or sequentially.", "LBL": "0", "DRUGA": ["polymyxin B", "drug", "164-174"], "DRUGB": ["colistin", "drug", "177-184"]}
{"ID": "DDI-DrugBank.d669.s1.p16", "TEXT1": "If other potentially toxic drugs are used concurrently or sequentially, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, careful monitoring is required.", "LBL": "0", "DRUGA": ["polymyxin B", "drug", "164-174"], "DRUGB": ["viomycin", "drug", "187-194"]}
{"ID": "DDI-DrugBank.d669.s1.p17", "TEXT1": "Concurrent and/or sequential systemic or topical use of other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, requires careful monitoring and communication with your healthcare team.", "LBL": "0", "DRUGA": ["polymyxin B", "drug", "164-174"], "DRUGB": ["cisplatin", "drug", "200-208"]}
{"ID": "DDI-DrugBank.d669.s1.p18", "TEXT1": "When other potentially neurotoxic and/or nephrotoxic drugs are used concurrently or sequentially, careful monitoring is required.", "LBL": "0", "DRUGA": ["colistin", "drug", "177-184"], "DRUGB": ["viomycin", "drug", "187-194"]}
{"ID": "DDI-DrugBank.d669.s1.p19", "TEXT1": "Other potentially neurotoxic and/or nephrotoxic drugs, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, when indicated, require concurrent and/or sequential systemic or topical use with @DRUG$ , which necessitates careful monitoring.", "LBL": "0", "DRUGA": ["colistin", "drug", "177-184"], "DRUGB": ["cisplatin", "drug", "200-208"]}
{"ID": "DDI-DrugBank.d669.s1.p20", "TEXT1": "When other potentially neurotoxic and/or nephrotoxic drugs are used concurrently or sequentially, such as amphotericin B, aminoglycosides, bacitracin, polymyxin B, colistin, viomycin, or cisplatin, careful monitoring is required.", "LBL": "0", "DRUGA": ["viomycin", "drug", "187-194"], "DRUGB": ["cisplatin", "drug", "200-208"]}
{"ID": "DDI-DrugBank.d590.s0.p0", "TEXT1": "Coadministration of TRITEC with clarithromycin may increase plasma ranitidine concentrations (57%), increase plasma bismuth trough concentrations (48%), and increase 14- hydroxy- clarithromycin plasma concentrations (31%).", "LBL": "DDI-mechanism", "DRUGA": ["TRITEC", "brand", "20-25"], "DRUGB": ["clarithromycin", "drug", "32-45"]}
{"ID": "DDI-DrugBank.d590.s0.p1", "TEXT1": "Coadministration of TRITEC with clarithromycin may result in increased plasma ranitidine concentrations, increased plasma bismuth trough concentrations, and increased 14- hydroxy- clarithromycin plasma concentrations.", "LBL": "0", "DRUGA": ["TRITEC", "brand", "20-25"], "DRUGB": ["ranitidine", "drug", "76-85"]}
{"ID": "DDI-DrugBank.d590.s0.p2", "TEXT1": "If TRITEC and clarithromycin are taken at the same time, ranitidine and bismuth concentrations in the blood may increase. There is also a possibility that the concentration of 14-hydroxy-clarithromycin will increase.", "LBL": "0", "DRUGA": ["TRITEC", "brand", "20-25"], "DRUGB": ["14- hydroxy- clarithromycin", "drug_n", "177-203"]}
{"ID": "DDI-DrugBank.d590.s0.p3", "TEXT1": "The concurrent administration of TRITEC and clarithromycin resulted in increased plasma concentrations of ranitidine (57%), bismuth (48%), and 14-hydroxy-clarithromycin (31%).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "32-45"], "DRUGB": ["ranitidine", "drug", "76-85"]}
{"ID": "DDI-DrugBank.d590.s0.p4", "TEXT1": "Coadministration of TRITEC with clarithromycin may result in increased plasma concentrations of ranitidine (57%), bismuth (48%), and 14-hydroxy-clarithromycin (31%).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "32-45"], "DRUGB": ["14- hydroxy- clarithromycin", "drug_n", "177-203"]}
{"ID": "DDI-DrugBank.d590.s0.p5", "TEXT1": "Coadministration of TRITEC with clarithromycin resulted in higher plasma ranitidine concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14- hydroxy- clarithromycin plasma concentrations (31%).", "LBL": "0", "DRUGA": ["ranitidine", "drug", "76-85"], "DRUGB": ["14- hydroxy- clarithromycin", "drug_n", "177-203"]}
{"ID": "DDI-DrugBank.d590.s1.p0", "TEXT1": "Coadministration with aspirin leads to a small decrease in the rate of salicylate absorption, which is not clinically significant.", "LBL": "0", "DRUGA": ["aspirin", "brand", "22-28"], "DRUGB": ["salicylate", "group", "74-83"]}
{"ID": "DDI-DrugBank.d590.s2.p0", "TEXT1": "When used together, ranitidine and bismuth levels may decrease. It is recommended to exercise caution when using these drugs together.", "LBL": "DDI-mechanism", "DRUGA": ["antacid", "group", "37-43"], "DRUGB": ["ranitidine", "drug", "109-118"]}
{"ID": "DDI-DrugBank.d590.s2.p1", "TEXT1": "Coadministration of antacid (170 mEq) with a high dose of ranitidine may decrease plasma concentrations of bismuth from TRITEC by 28%.", "LBL": "DDI-mechanism", "DRUGA": ["antacid", "group", "37-43"], "DRUGB": ["TRITEC", "brand", "175-180"]}
{"ID": "DDI-DrugBank.d590.s2.p2", "TEXT1": "Coadministration with a high dose of antacid (170 mEq) may result in a decrease in plasma concentrations of ranitidine and bismuth from TRITEC.", "LBL": "0", "DRUGA": ["ranitidine", "drug", "109-118"], "DRUGB": ["TRITEC", "brand", "175-180"]}
{"ID": "DDI-DrugBank.d590.s4.p0", "TEXT1": "For information on drug interactions associated with ranitidine, please refer to the ZANTAC package insert.", "LBL": "0", "DRUGA": ["ranitidine", "drug", "53-62"], "DRUGB": ["ZANTAC", "brand", "78-83"]}
{"ID": "DDI-DrugBank.d702.s1.p0", "TEXT1": "Other drugs that may interact with AUGMENTIN XR include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids.", "LBL": "0", "DRUGA": ["sympathomimetic bronchodilators", "group", "14-44"], "DRUGB": ["methylxanthines", "group", "47-61"]}
{"ID": "DDI-DrugBank.d702.s1.p1", "TEXT1": "These include sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids which could potentially help with the patients' condition.", "LBL": "0", "DRUGA": ["sympathomimetic bronchodilators", "group", "14-44"], "DRUGB": ["steroids", "group", "85-92"]}
{"ID": "DDI-DrugBank.d702.s1.p2", "TEXT1": "The concurrent administration of @DRUG$ and @DRUG$ is not recommended. This includes sympathomimetic bronchodilators, methylxanthines, and oral and inhaled steroids.", "LBL": "0", "DRUGA": ["methylxanthines", "group", "47-61"], "DRUGB": ["steroids", "group", "85-92"]}
{"ID": "DDI-DrugBank.d702.s2.p0", "TEXT1": "However, the administration of SPIRIVA with other anticholinergic drugs has not been studied. Therefore, it is not recommended.", "LBL": "DDI-advise", "DRUGA": ["SPIRIVA", "brand", "36-42"], "DRUGB": ["anticholinergic", "group", "55-69"]}
{"ID": "DDI-DrugBank.d702.s2.p1", "TEXT1": "The co-administration of SPIRIVA with other anticholinergic-containing drugs has not been studied and is therefore not recommended.", "LBL": "DDI-advise", "DRUGA": ["SPIRIVA", "brand", "36-42"], "DRUGB": ["ipratropium", "drug", "97-107"]}
{"ID": "DDI-DrugBank.d702.s2.p2", "TEXT1": "However, the co-administration of SPIRIVA with other drugs that contain anticholinergic substances (e.g., ipratropium) has not been studied and is therefore not recommended.", "LBL": "0", "DRUGA": ["anticholinergic", "group", "55-69"], "DRUGB": ["ipratropium", "drug", "97-107"]}
{"ID": "DDI-DrugBank.d642.s0.p0", "TEXT1": "If tigecycline is administered with warfarin, prothrombin time or other suitable anticoagulation tests should be monitored.", "LBL": "DDI-advise", "DRUGA": ["tigecycline", "drug", "79-89"], "DRUGB": ["warfarin", "drug", "112-119"]}
{"ID": "DDI-DrugBank.d642.s1.p0", "TEXT1": "Concomitant use of antibacterial drugs and oral contraceptives may decrease the effectiveness of the oral contraceptives.", "LBL": "DDI-effect", "DRUGA": ["antibacterial drugs", "group", "18-36"], "DRUGB": ["contraceptives", "group", "48-61"]}
{"ID": "DDI-DrugBank.d642.s1.p1", "TEXT1": "Concurrent use of antibacterial drugs with oral contraceptives may make oral contraceptives less effective.", "LBL": "0", "DRUGA": ["antibacterial drugs", "group", "18-36"], "DRUGB": ["contraceptives", "group", "79-92"]}
{"ID": "DDI-DrugBank.d642.s1.p2", "TEXT1": "Concurrent use of antibacterial drugs with oral contraceptives can render oral contraceptives less effective.", "LBL": "0", "DRUGA": ["contraceptives", "group", "48-61"], "DRUGB": ["contraceptives", "group", "79-92"]}
{"ID": "DDI-DrugBank.d615.s0.p0", "TEXT1": "Caution is recommended when using triprolidine with central nervous system depressants like alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "DDI-effect", "DRUGA": ["Triprolidine", "drug", "0-11"], "DRUGB": ["central nervous system depressants", "group", "49-82"]}
{"ID": "DDI-DrugBank.d615.s0.p1", "TEXT1": "If triprolidine and central nervous system depressants are used together, it is recommended to exercise caution. This includes using alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "DDI-effect", "DRUGA": ["Triprolidine", "drug", "0-11"], "DRUGB": ["alcohol", "drug", "94-100"]}
{"ID": "DDI-DrugBank.d615.s0.p2", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants, including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "DDI-effect", "DRUGA": ["Triprolidine", "drug", "0-11"], "DRUGB": ["barbiturates", "group", "103-114"]}
{"ID": "DDI-DrugBank.d615.s0.p3", "TEXT1": "Triprolidine may intensify the sedative effects of central nervous system depressants like alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "DDI-effect", "DRUGA": ["Triprolidine", "drug", "0-11"], "DRUGB": ["hypnotics", "group", "117-125"]}
{"ID": "DDI-DrugBank.d615.s0.p4", "TEXT1": "The sedative effects of triprolidine may be enhanced by central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "DDI-effect", "DRUGA": ["Triprolidine", "drug", "0-11"], "DRUGB": ["narcotic analgesics", "group", "128-146"]}
{"ID": "DDI-DrugBank.d615.s0.p5", "TEXT1": "Triprolidine may intensify the sedative effects of central nervous system depressants like alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "DDI-effect", "DRUGA": ["Triprolidine", "drug", "0-11"], "DRUGB": ["sedatives", "group", "149-157"]}
{"ID": "DDI-DrugBank.d615.s0.p6", "TEXT1": "Caution is recommended when using triprolidine with central nervous system depressants such as alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, or tranquillisers.", "LBL": "DDI-effect", "DRUGA": ["Triprolidine", "drug", "0-11"], "DRUGB": ["tranquillisers", "group", "164-177"]}
{"ID": "DDI-DrugBank.d615.s0.p7", "TEXT1": "Triprolidine can increase the drowsy effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["central nervous system depressants", "group", "49-82"], "DRUGB": ["alcohol", "drug", "94-100"]}
{"ID": "DDI-DrugBank.d615.s0.p8", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquilizers.", "LBL": "0", "DRUGA": ["central nervous system depressants", "group", "49-82"], "DRUGB": ["barbiturates", "group", "103-114"]}
{"ID": "DDI-DrugBank.d615.s0.p9", "TEXT1": "The concomitant use of triprolidine with central nervous system depressants such as alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers may enhance sedative effects.", "LBL": "0", "DRUGA": ["central nervous system depressants", "group", "49-82"], "DRUGB": ["hypnotics", "group", "117-125"]}
{"ID": "DDI-DrugBank.d615.s0.p10", "TEXT1": "Caution is recommended if triprolidine is used in combination with central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["central nervous system depressants", "group", "49-82"], "DRUGB": ["narcotic analgesics", "group", "128-146"]}
{"ID": "DDI-DrugBank.d615.s0.p11", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants, including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["central nervous system depressants", "group", "49-82"], "DRUGB": ["sedatives", "group", "149-157"]}
{"ID": "DDI-DrugBank.d615.s0.p12", "TEXT1": "Triprolidine may help to intensify the sedative effects of central nervous system depressants such as alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["central nervous system depressants", "group", "49-82"], "DRUGB": ["tranquillisers", "group", "164-177"]}
{"ID": "DDI-DrugBank.d615.s0.p13", "TEXT1": "Caution may be warranted when triprolidine is used in combination with central nervous system depressants such as alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["alcohol", "drug", "94-100"], "DRUGB": ["barbiturates", "group", "103-114"]}
{"ID": "DDI-DrugBank.d615.s0.p14", "TEXT1": "Triprolidine may intensify the sedative effects of central nervous system depressants, including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["alcohol", "drug", "94-100"], "DRUGB": ["hypnotics", "group", "117-125"]}
{"ID": "DDI-DrugBank.d615.s0.p15", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["alcohol", "drug", "94-100"], "DRUGB": ["narcotic analgesics", "group", "128-146"]}
{"ID": "DDI-DrugBank.d615.s0.p16", "TEXT1": "Triprolidine may intensify the drowsy effects of central nervous system depressants like alcohol, barbiturates, hypnotics, narcotic painkillers, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["alcohol", "drug", "94-100"], "DRUGB": ["sedatives", "group", "149-157"]}
{"ID": "DDI-DrugBank.d615.s0.p17", "TEXT1": "Triprolidine may amplify the sedative effects of central nervous system depressants like alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["alcohol", "drug", "94-100"], "DRUGB": ["tranquillisers", "group", "164-177"]}
{"ID": "DDI-DrugBank.d615.s0.p18", "TEXT1": "Triprolidine may intensify the sedative effects of central nervous system depressants like alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["barbiturates", "group", "103-114"], "DRUGB": ["hypnotics", "group", "117-125"]}
{"ID": "DDI-DrugBank.d615.s0.p19", "TEXT1": "Caution is recommended when using triprolidine with central nervous system depressants, including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["barbiturates", "group", "103-114"], "DRUGB": ["narcotic analgesics", "group", "128-146"]}
{"ID": "DDI-DrugBank.d615.s0.p20", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants, including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["barbiturates", "group", "103-114"], "DRUGB": ["sedatives", "group", "149-157"]}
{"ID": "DDI-DrugBank.d615.s0.p21", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["barbiturates", "group", "103-114"], "DRUGB": ["tranquillisers", "group", "164-177"]}
{"ID": "DDI-DrugBank.d615.s0.p22", "TEXT1": "Triprolidine may intensify the sedative effects of central nervous system depressants like alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["hypnotics", "group", "117-125"], "DRUGB": ["narcotic analgesics", "group", "128-146"]}
{"ID": "DDI-DrugBank.d615.s0.p23", "TEXT1": "Triprolidine may intensify the sedative effects of central nervous system depressants, including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["hypnotics", "group", "117-125"], "DRUGB": ["sedatives", "group", "149-157"]}
{"ID": "DDI-DrugBank.d615.s0.p24", "TEXT1": "The sedative effects of Triprolidine may be enhanced when taken with central nervous system depressants such as alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["hypnotics", "group", "117-125"], "DRUGB": ["tranquillisers", "group", "164-177"]}
{"ID": "DDI-DrugBank.d615.s0.p25", "TEXT1": "Triprolidine may enhance the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["narcotic analgesics", "group", "128-146"], "DRUGB": ["sedatives", "group", "149-157"]}
{"ID": "DDI-DrugBank.d615.s0.p26", "TEXT1": "Triprolidine may increase the sedative effects of central nervous system depressants including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["narcotic analgesics", "group", "128-146"], "DRUGB": ["tranquillisers", "group", "164-177"]}
{"ID": "DDI-DrugBank.d615.s0.p27", "TEXT1": "Triprolidine may amplify the sedative effects of central nervous system depressants, including alcohol, barbiturates, hypnotics, narcotic analgesics, sedatives, and tranquillisers.", "LBL": "0", "DRUGA": ["sedatives", "group", "149-157"], "DRUGB": ["tranquillisers", "group", "164-177"]}
{"ID": "DDI-DrugBank.d615.s1.p0", "TEXT1": "The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants, may be enhanced when triprolidine is administered at the same time.", "LBL": "0", "DRUGA": ["anticholinergic drugs", "group", "15-35"], "DRUGB": ["atropine", "drug", "46-53"]}
{"ID": "DDI-DrugBank.d615.s1.p1", "TEXT1": "The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants, may be enhanced when triprolidine is taken at the same time.", "LBL": "0", "DRUGA": ["anticholinergic drugs", "group", "15-35"], "DRUGB": ["tricyclic antidepressants", "group", "59-83"]}
{"ID": "DDI-DrugBank.d615.s1.p2", "TEXT1": "The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants may be more pronounced when triprolidine is also taken.", "LBL": "DDI-effect", "DRUGA": ["anticholinergic drugs", "group", "15-35"], "DRUGB": ["triprolidine", "drug", "138-149"]}
{"ID": "DDI-DrugBank.d615.s1.p3", "TEXT1": "The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants, may be enhanced by the concomitant administration of triprolidine.", "LBL": "0", "DRUGA": ["atropine", "drug", "46-53"], "DRUGB": ["tricyclic antidepressants", "group", "59-83"]}
{"ID": "DDI-DrugBank.d615.s1.p4", "TEXT1": "It is possible that the effects of anticholinergic drugs, such as atropine and tricyclic antidepressants, may be enhanced by the concomitant administration of triprolidine.", "LBL": "DDI-effect", "DRUGA": ["atropine", "drug", "46-53"], "DRUGB": ["triprolidine", "drug", "138-149"]}
{"ID": "DDI-DrugBank.d615.s1.p5", "TEXT1": "The effects of anticholinergic drugs, such as atropine and tricyclic antidepressants, may be enhanced when triprolidine is taken at the same time.", "LBL": "DDI-effect", "DRUGA": ["tricyclic antidepressants", "group", "59-83"], "DRUGB": ["triprolidine", "drug", "138-149"]}
{"ID": "DDI-DrugBank.d675.s0.p0", "TEXT1": "There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.", "LBL": "0", "DRUGA": ["Macrolide Antibiotics", "group", "25-45"], "DRUGB": ["Protease Inhibitors", "group", "51-69"]}
{"ID": "DDI-DrugBank.d675.s0.p1", "TEXT1": "There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors. These events have resulted in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.", "LBL": "0", "DRUGA": ["Macrolide Antibiotics", "group", "25-45"], "DRUGB": ["ergot alkaloid drugs", "group", "178-197"]}
{"ID": "DDI-DrugBank.d675.s0.p2", "TEXT1": "There have been rare reports of serious adverse events when certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) are taken with potent CYP 3A4 inhibitors. These events can cause vasospasm leading to cerebral ischemia and/or ischemia of the extremities.", "LBL": "0", "DRUGA": ["Macrolide Antibiotics", "group", "25-45"], "DRUGB": ["dihydroergotamine", "drug", "205-221"]}
{"ID": "DDI-DrugBank.d675.s0.p3", "TEXT1": "There have been a few reports of serious side effects when certain drugs in the ergot alkaloid class (such as dihydroergotamine and ergotamine) are taken together with potent CYP 3A4 inhibitors. These events can include vasospasm that leads to cerebral ischemia (reduced blood flow to the brain) and/or ischemia of the extremities (reduced blood flow to the arms and legs).", "LBL": "0", "DRUGA": ["Macrolide Antibiotics", "group", "25-45"], "DRUGB": ["ergotamine", "drug", "227-236"]}
{"ID": "DDI-DrugBank.d675.s0.p4", "TEXT1": "There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors. These events have been characterized by vasospasm leading to cerebral ischemia and/or ischemia of the extremities.", "LBL": "0", "DRUGA": ["Protease Inhibitors", "group", "51-69"], "DRUGB": ["ergot alkaloid drugs", "group", "178-197"]}
{"ID": "DDI-DrugBank.d675.s0.p5", "TEXT1": "There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.", "LBL": "0", "DRUGA": ["Protease Inhibitors", "group", "51-69"], "DRUGB": ["dihydroergotamine", "drug", "205-221"]}
{"ID": "DDI-DrugBank.d675.s0.p6", "TEXT1": "CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been some reports of adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.", "LBL": "0", "DRUGA": ["Protease Inhibitors", "group", "51-69"], "DRUGB": ["ergotamine", "drug", "227-236"]}
{"ID": "DDI-DrugBank.d675.s0.p7", "TEXT1": "There have been some rare reports of serious adverse events when certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) are taken with potent CYP 3A4 inhibitors. This can cause vasospasm leading to cerebral ischemia and/or ischemia of the extremities.", "LBL": "0", "DRUGA": ["ergot alkaloid drugs", "group", "178-197"], "DRUGB": ["dihydroergotamine", "drug", "205-221"]}
{"ID": "DDI-DrugBank.d675.s0.p8", "TEXT1": "There have been rare reports of serious adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors. These events have resulted in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.", "LBL": "0", "DRUGA": ["ergot alkaloid drugs", "group", "178-197"], "DRUGB": ["ergotamine", "drug", "227-236"]}
{"ID": "DDI-DrugBank.d675.s0.p9", "TEXT1": "CYP 3A4 Inhibitors (e.g. Macrolide Antibiotics and Protease Inhibitors) There have been rare reports of adverse events in connection with the coadministration of certain ergot alkaloid drugs (e.g. dihydroergotamine and ergotamine) and potent CYP 3A4 inhibitors, resulting in vasospasm leading to cerebral ischemia and/or ischemia of the extremities.", "LBL": "0", "DRUGA": ["dihydroergotamine", "drug", "205-221"], "DRUGB": ["ergotamine", "drug", "227-236"]}
{"ID": "DDI-DrugBank.d675.s2.p0", "TEXT1": "Some examples of CYP 3A4 inhibitors that are more potent include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["erythromycin", "drug", "92-103"]}
{"ID": "DDI-DrugBank.d675.s2.p1", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["troleandomycin", "drug", "106-119"]}
{"ID": "DDI-DrugBank.d675.s2.p2", "TEXT1": "Some examples of more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine), or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["clarithromycin", "drug", "122-135"]}
{"ID": "DDI-DrugBank.d675.s2.p3", "TEXT1": "There are some more potent CYP 3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine), or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["HIV protease inhibitors", "group", "139-150;177-186"]}
{"ID": "DDI-DrugBank.d675.s2.p4", "TEXT1": "Some examples of more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["reverse transcriptase inhibitors", "group", "155-186"]}
{"ID": "DDI-DrugBank.d675.s2.p5", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (such as erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (like ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (including ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["ritonavir", "drug", "195-203"]}
{"ID": "DDI-DrugBank.d675.s2.p6", "TEXT1": "Some examples of potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). These drugs may interfere with the absorption of @DRUG$.", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["indinavir", "drug", "206-214"]}
{"ID": "DDI-DrugBank.d675.s2.p7", "TEXT1": "Some CYP 3A4 inhibitors that are more potent include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["nelfinavir", "drug", "217-226"]}
{"ID": "DDI-DrugBank.d675.s2.p8", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["delavirdine", "drug", "229-239"]}
{"ID": "DDI-DrugBank.d675.s2.p9", "TEXT1": "Some examples of CYP 3A4 inhibitors that can have a more potent effect include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["azole antifungals", "group", "245-261"]}
{"ID": "DDI-DrugBank.d675.s2.p10", "TEXT1": "Some examples of more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p11", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p12", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["macrolide antibiotics", "group", "63-83"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p13", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["troleandomycin", "drug", "106-119"]}
{"ID": "DDI-DrugBank.d675.s2.p14", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["clarithromycin", "drug", "122-135"]}
{"ID": "DDI-DrugBank.d675.s2.p15", "TEXT1": "Some drugs which may interfere with the absorption of @DRUG$ include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["HIV protease inhibitors", "group", "139-150;177-186"]}
{"ID": "DDI-DrugBank.d675.s2.p16", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["reverse transcriptase inhibitors", "group", "155-186"]}
{"ID": "DDI-DrugBank.d675.s2.p17", "TEXT1": "Some examples of CYP 3A4 inhibitors that may have a stronger effect include macrolide antibiotics (such as erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (such as ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (such as ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["ritonavir", "drug", "195-203"]}
{"ID": "DDI-DrugBank.d675.s2.p18", "TEXT1": "Some of the potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["indinavir", "drug", "206-214"]}
{"ID": "DDI-DrugBank.d675.s2.p19", "TEXT1": "Some CYP 3A4 inhibitors that are more potent include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["nelfinavir", "drug", "217-226"]}
{"ID": "DDI-DrugBank.d675.s2.p20", "TEXT1": "Some potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["delavirdine", "drug", "229-239"]}
{"ID": "DDI-DrugBank.d675.s2.p21", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["azole antifungals", "group", "245-261"]}
{"ID": "DDI-DrugBank.d675.s2.p22", "TEXT1": "Some examples of CYP 3A4 inhibitors that should be used with caution include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p23", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). These medications can keep the plasma concentrations of @DRUG$ at approximately 50%.", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p24", "TEXT1": "CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole), which are more potent.", "LBL": "0", "DRUGA": ["erythromycin", "drug", "92-103"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p25", "TEXT1": "Some examples of medications that can interfere with @DRUG$ include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine), and azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["clarithromycin", "drug", "122-135"]}
{"ID": "DDI-DrugBank.d675.s2.p26", "TEXT1": "CYP 3A4 inhibitors that are more potent include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["HIV protease inhibitors", "group", "139-150;177-186"]}
{"ID": "DDI-DrugBank.d675.s2.p27", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). However, these medications may still be effective when used in combination with AUGMENTIN XR.", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["reverse transcriptase inhibitors", "group", "155-186"]}
{"ID": "DDI-DrugBank.d675.s2.p28", "TEXT1": "Some examples of CYP 3A4 inhibitors which are more potent include macrolide antibiotics (such as erythromycin, troleandomycin, or clarithromycin), HIV protease or reverse transcriptase inhibitors (such as ritonavir, indinavir, nelfinavir, or delavirdine), or azole antifungals (like ketoconazole, itraconazole, or voriconazole).", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["ritonavir", "drug", "195-203"]}
{"ID": "DDI-DrugBank.d675.s2.p29", "TEXT1": "CYP 3A4 inhibitors that are more potent include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["indinavir", "drug", "206-214"]}
{"ID": "DDI-DrugBank.d675.s2.p30", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (ketoconazole, itraconazole, voriconazole). If these are used in combination with @DRUG$, exercise caution.", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["nelfinavir", "drug", "217-226"]}
{"ID": "DDI-DrugBank.d675.s2.p31", "TEXT1": "Some more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["delavirdine", "drug", "229-239"]}
{"ID": "DDI-DrugBank.d675.s2.p32", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["azole antifungals", "group", "245-261"]}
{"ID": "DDI-DrugBank.d675.s2.p33", "TEXT1": "CYP 3A4 inhibitors can include macrolide antibiotics (like erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (like ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (like ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p34", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p35", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["troleandomycin", "drug", "106-119"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p36", "TEXT1": "CYP 3A4 inhibitors can include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). These substances can potentially interact with @DRUG$.", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "122-135"], "DRUGB": ["HIV protease inhibitors", "group", "139-150;177-186"]}
{"ID": "DDI-DrugBank.d675.s2.p37", "TEXT1": "Some examples of CYP 3A4 inhibitors that are more potent include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "122-135"], "DRUGB": ["reverse transcriptase inhibitors", "group", "155-186"]}
{"ID": "DDI-DrugBank.d675.s2.p38", "TEXT1": "Some CYP 3A4 inhibitors that are more potent include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "122-135"], "DRUGB": ["ritonavir", "drug", "195-203"]}
{"ID": "DDI-DrugBank.d675.s2.p39", "TEXT1": "Some examples of more potent CYP 3A4 inhibitors include macrolide antibiotics (such as erythromycin, troleandomycin, or clarithromycin), HIV protease or reverse transcriptase inhibitors (like ritonavir, indinavir, nelfinavir, or delavirdine), or azole antifungals (for example, ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "122-135"], "DRUGB": ["indinavir", "drug", "206-214"]}
{"ID": "DDI-DrugBank.d675.s2.p40", "TEXT1": "CYP 3A4 inhibitors can include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "122-135"], "DRUGB": ["nelfinavir", "drug", "217-226"]}
{"ID": "DDI-DrugBank.d675.s2.p41", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "122-135"], "DRUGB": ["delavirdine", "drug", "229-239"]}
{"ID": "DDI-DrugBank.d675.s2.p42", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "122-135"], "DRUGB": ["azole antifungals", "group", "245-261"]}
{"ID": "DDI-DrugBank.d675.s2.p43", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "122-135"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p44", "TEXT1": "Some drugs which may inhibit the absorption of @DRUG$ include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "122-135"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p45", "TEXT1": "Some examples of potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["clarithromycin", "drug", "122-135"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p46", "TEXT1": "There are some CYP 3A4 inhibitors which are potent, for example macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["HIV protease inhibitors", "group", "139-150;177-186"], "DRUGB": ["reverse transcriptase inhibitors", "group", "155-186"]}
{"ID": "DDI-DrugBank.d675.s2.p47", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["HIV protease inhibitors", "group", "139-150;177-186"], "DRUGB": ["ritonavir", "drug", "195-203"]}
{"ID": "DDI-DrugBank.d675.s2.p48", "TEXT1": "Some CYP 3A4 inhibitors that could potentially have a stronger effect include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["HIV protease inhibitors", "group", "139-150;177-186"], "DRUGB": ["indinavir", "drug", "206-214"]}
{"ID": "DDI-DrugBank.d675.s2.p49", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["HIV protease inhibitors", "group", "139-150;177-186"], "DRUGB": ["nelfinavir", "drug", "217-226"]}
{"ID": "DDI-DrugBank.d675.s2.p50", "TEXT1": "Examples of CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["HIV protease inhibitors", "group", "139-150;177-186"], "DRUGB": ["delavirdine", "drug", "229-239"]}
{"ID": "DDI-DrugBank.d675.s2.p51", "TEXT1": "Some potential CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["HIV protease inhibitors", "group", "139-150;177-186"], "DRUGB": ["azole antifungals", "group", "245-261"]}
{"ID": "DDI-DrugBank.d675.s2.p52", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["HIV protease inhibitors", "group", "139-150;177-186"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p53", "TEXT1": "Some examples of more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["HIV protease inhibitors", "group", "139-150;177-186"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p54", "TEXT1": "Some of the CYP 3A4 inhibitors that are more potent include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["HIV protease inhibitors", "group", "139-150;177-186"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p55", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["reverse transcriptase inhibitors", "group", "155-186"], "DRUGB": ["ritonavir", "drug", "195-203"]}
{"ID": "DDI-DrugBank.d675.s2.p56", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["reverse transcriptase inhibitors", "group", "155-186"], "DRUGB": ["indinavir", "drug", "206-214"]}
{"ID": "DDI-DrugBank.d739.s8.p1", "TEXT1": "When potent cytochrome P450 enzyme inducers, such as phenobarbital or rifampin, are co-administered with montelukast, it is appropriate to use clinical monitoring.", "LBL": "DDI-advise", "DRUGA": ["phenobarbital", "drug", "112-124"], "DRUGB": ["montelukast", "drug", "164-174"]}
{"ID": "DDI-DrugBank.d675.s2.p58", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["reverse transcriptase inhibitors", "group", "155-186"], "DRUGB": ["delavirdine", "drug", "229-239"]}
{"ID": "DDI-DrugBank.d675.s2.p59", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["reverse transcriptase inhibitors", "group", "155-186"], "DRUGB": ["azole antifungals", "group", "245-261"]}
{"ID": "DDI-DrugBank.d675.s2.p60", "TEXT1": "Some examples of potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["reverse transcriptase inhibitors", "group", "155-186"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p61", "TEXT1": "Some potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["reverse transcriptase inhibitors", "group", "155-186"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p62", "TEXT1": "Some examples of CYP 3A4 inhibitors that are more potent include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["reverse transcriptase inhibitors", "group", "155-186"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p63", "TEXT1": "Some CYP 3A4 inhibitors that may interfere with the absorption of @DRUG$ include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["ritonavir", "drug", "195-203"], "DRUGB": ["indinavir", "drug", "206-214"]}
{"ID": "DDI-DrugBank.d675.s2.p64", "TEXT1": "The concomitant administration of the following drugs is contraindicated: macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["ritonavir", "drug", "195-203"], "DRUGB": ["nelfinavir", "drug", "217-226"]}
{"ID": "DDI-DrugBank.d675.s2.p65", "TEXT1": "Certain CYP 3A4 inhibitors, such as macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole), may interfere with the absorption of @DRUG$.", "LBL": "0", "DRUGA": ["ritonavir", "drug", "195-203"], "DRUGB": ["delavirdine", "drug", "229-239"]}
{"ID": "DDI-DrugBank.d675.s2.p66", "TEXT1": "Some examples of potentially more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine), or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["ritonavir", "drug", "195-203"], "DRUGB": ["azole antifungals", "group", "245-261"]}
{"ID": "DDI-DrugBank.d675.s2.p67", "TEXT1": "Some examples of more potent CYP 3A4 inhibitors include macrolide antibiotics (erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (ritonavir, indinavir, nelfinavir, delavirdine), or azole antifungals (ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["ritonavir", "drug", "195-203"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p68", "TEXT1": "Some of the more powerful CYP 3A4 inhibitors include macrolide antibiotics (such as erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (such as ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (such as ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["ritonavir", "drug", "195-203"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p69", "TEXT1": "Some examples of CYP 3A4 inhibitors that may have a stronger effect include macrolide antibiotics (such as erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (like ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (for example, ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["ritonavir", "drug", "195-203"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p70", "TEXT1": "Some of the CYP 3A4 inhibitors that are more potent include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["indinavir", "drug", "206-214"], "DRUGB": ["nelfinavir", "drug", "217-226"]}
{"ID": "DDI-DrugBank.d675.s2.p71", "TEXT1": "There are a number of potent CYP 3A4 inhibitors, including macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["indinavir", "drug", "206-214"], "DRUGB": ["delavirdine", "drug", "229-239"]}
{"ID": "DDI-DrugBank.d675.s2.p72", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["indinavir", "drug", "206-214"], "DRUGB": ["azole antifungals", "group", "245-261"]}
{"ID": "DDI-DrugBank.d675.s2.p73", "TEXT1": "Some examples of CYP 3A4 inhibitors which are more potent include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["indinavir", "drug", "206-214"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p74", "TEXT1": "Examples of some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). These drugs can increase the levels of @DRUG$ in the body, which may lead to adverse effects.", "LBL": "0", "DRUGA": ["indinavir", "drug", "206-214"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p75", "TEXT1": "Some examples of potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["indinavir", "drug", "206-214"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p76", "TEXT1": "CYP 3A4 inhibitors can include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole). These drugs can potentiate the effect of CYP 3A4 inhibitors.", "LBL": "0", "DRUGA": ["nelfinavir", "drug", "217-226"], "DRUGB": ["delavirdine", "drug", "229-239"]}
{"ID": "DDI-DrugBank.d675.s2.p77", "TEXT1": "Some examples of stronger CYP 3A4 inhibitors include macrolide antibiotics like erythromycin, troleandomycin, and clarithromycin, HIV protease or reverse transcriptase inhibitors like ritonavir, indinavir, nelfinavir, and delavirdine, and azole antifungals like ketoconazole, itraconazole, and voriconazole.", "LBL": "0", "DRUGA": ["nelfinavir", "drug", "217-226"], "DRUGB": ["azole antifungals", "group", "245-261"]}
{"ID": "DDI-DrugBank.d675.s2.p78", "TEXT1": "Pharmaceuticals that are CYP 3A4 inhibitors (for example, erythromycin, troleandomycin, clarithromycin, ritonavir, indinavir, nelfinavir, delavirdine, ketoconazole, itraconazole, voriconazole) can reduce the efficacy of AUGMENTIN XR.", "LBL": "0", "DRUGA": ["nelfinavir", "drug", "217-226"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p79", "TEXT1": "CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["nelfinavir", "drug", "217-226"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p80", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (such as erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (such as ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (such as ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["nelfinavir", "drug", "217-226"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p81", "TEXT1": "Some CYP 3A4 inhibitors that are more potent include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["delavirdine", "drug", "229-239"], "DRUGB": ["azole antifungals", "group", "245-261"]}
{"ID": "DDI-DrugBank.d675.s2.p82", "TEXT1": "CYP 3A4 inhibitors such as macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole) can potentiate the effects of @DRUG$.", "LBL": "0", "DRUGA": ["delavirdine", "drug", "229-239"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p83", "TEXT1": "Some of the better-known CYP 3A4 inhibitors include macrolide antibiotics (e.g. erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g. ritonavir, indinavir, nelfinavir, delavirdine), or azole antifungals (e.g. ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["delavirdine", "drug", "229-239"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p84", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["delavirdine", "drug", "229-239"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p85", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["azole antifungals", "group", "245-261"], "DRUGB": ["ketoconazole", "drug", "270-281"]}
{"ID": "DDI-DrugBank.d675.s2.p86", "TEXT1": "Some of the CYP 3A4 inhibitors that are more potent include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["azole antifungals", "group", "245-261"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p87", "TEXT1": "Some examples of more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["azole antifungals", "group", "245-261"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p88", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "270-281"], "DRUGB": ["itraconazole", "drug", "284-295"]}
{"ID": "DDI-DrugBank.d675.s2.p89", "TEXT1": "Some CYP 3A4 inhibitors that may cause more pronounced effects include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["ketoconazole", "drug", "270-281"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s2.p90", "TEXT1": "Some of the more potent CYP 3A4 inhibitors include macrolide antibiotics (e.g., erythromycin, troleandomycin, clarithromycin), HIV protease or reverse transcriptase inhibitors (e.g., ritonavir, indinavir, nelfinavir, delavirdine) or azole antifungals (e.g., ketoconazole, itraconazole, voriconazole).", "LBL": "0", "DRUGA": ["itraconazole", "drug", "284-295"], "DRUGB": ["voriconazole", "drug", "298-309"]}
{"ID": "DDI-DrugBank.d675.s4.p0", "TEXT1": "Some less potent inhibitors include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.", "LBL": "0", "DRUGA": ["saquinavir", "drug", "31-40"], "DRUGB": ["nefazodone", "drug", "43-52"]}
{"ID": "DDI-DrugBank.d675.s4.p1", "TEXT1": "Some inhibitors that are less potent include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.", "LBL": "0", "DRUGA": ["saquinavir", "drug", "31-40"], "DRUGB": ["fluconazole", "drug", "55-65"]}
{"ID": "DDI-DrugBank.d675.s4.p2", "TEXT1": "Inhibitors that are less potent include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.", "LBL": "0", "DRUGA": ["saquinavir", "drug", "31-40"], "DRUGB": ["fluoxetine", "drug", "86-95"]}
{"ID": "DDI-DrugBank.d675.s4.p3", "TEXT1": "In common with other medications, AUGMENTIN XR may change the efficacy of oral contraceptives.", "LBL": "0", "DRUGA": ["saquinavir", "drug", "31-40"], "DRUGB": ["fluvoxamine", "drug", "98-108"]}
{"ID": "DDI-DrugBank.d675.s4.p4", "TEXT1": "If you are taking @DRUG$, it is important to be aware that there are other, less potent inhibitors that could potentially interact with the drug. These include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.", "LBL": "0", "DRUGA": ["saquinavir", "drug", "31-40"], "DRUGB": ["zileuton", "drug", "111-118"]}
{"ID": "DDI-DrugBank.d675.s4.p5", "TEXT1": "Less potent inhibitors of @DRUG$ include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.", "LBL": "0", "DRUGA": ["saquinavir", "drug", "31-40"], "DRUGB": ["clotrimazole", "drug", "125-136"]}
{"ID": "DDI-DrugBank.d675.s4.p6", "TEXT1": "Other less potent inhibitors of @DRUG$ include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.", "LBL": "0", "DRUGA": ["nefazodone", "drug", "43-52"], "DRUGB": ["fluconazole", "drug", "55-65"]}
{"ID": "DDI-DrugBank.d675.s4.p7", "TEXT1": "Some potential inhibitors of CYP3A4 that may have a less significant effect include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.", "LBL": "0", "DRUGA": ["nefazodone", "drug", "43-52"], "DRUGB": ["fluoxetine", "drug", "86-95"]}
{"ID": "DDI-DrugBank.d675.s4.p8", "TEXT1": "Some less potent inhibitors of the drug include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.", "LBL": "0", "DRUGA": ["nefazodone", "drug", "43-52"], "DRUGB": ["fluvoxamine", "drug", "98-108"]}
{"ID": "DDI-DrugBank.d675.s4.p9", "TEXT1": "Description: Less potent inhibitors of @DRUG$ include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.", "LBL": "0", "DRUGA": ["nefazodone", "drug", "43-52"], "DRUGB": ["zileuton", "drug", "111-118"]}
{"ID": "DDI-DrugBank.d699.s0.p0", "TEXT1": "Mequitazine is known to interact with CNS depressants, anticholinergics, TCAs, MAOIs, and alcohol.", "LBL": "DDI-int", "DRUGA": ["Mequitazine", "drug", "0-10"], "DRUGB": ["CNS depressant", "group", "30-43"]}
{"ID": "DDI-DrugBank.d675.s4.p11", "TEXT1": "Inhibitors that are not as potent as @DRUG$ include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.", "LBL": "0", "DRUGA": ["fluconazole", "drug", "55-65"], "DRUGB": ["fluoxetine", "drug", "86-95"]}
{"ID": "DDI-DrugBank.d675.s4.p12", "TEXT1": "Index drugs that have a lower potential to interact with @DRUG$ include saquinavir, nefazodone, fluconazole, grapefruit juice, fluoxetine, fluvoxamine, zileuton, and clotrimazole.", "LBL": "0", "DRUGA": ["fluconazole", "drug", "55-65"], "DRUGB": ["fluvoxamine", "drug", "98-108"]}
